Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 8 | 2021 | 137 | 2.280 |
Why?
|
| Myocardial Infarction | 11 | 2016 | 807 | 1.970 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2014 | 212 | 1.190 |
Why?
|
| Coronary Artery Disease | 4 | 2020 | 696 | 1.130 |
Why?
|
| Radial Artery | 3 | 2021 | 43 | 1.040 |
Why?
|
| Hemorrhage | 3 | 2016 | 328 | 1.000 |
Why?
|
| Collateral Circulation | 2 | 2015 | 34 | 0.950 |
Why?
|
| Coronary Occlusion | 2 | 2015 | 12 | 0.940 |
Why?
|
| Drug-Eluting Stents | 3 | 2016 | 51 | 0.940 |
Why?
|
| Acute Coronary Syndrome | 4 | 2016 | 195 | 0.920 |
Why?
|
| Coronary Circulation | 3 | 2015 | 136 | 0.920 |
Why?
|
| Coronary Vessels | 2 | 2015 | 313 | 0.780 |
Why?
|
| Atherectomy, Coronary | 1 | 2020 | 5 | 0.750 |
Why?
|
| Catheterization, Peripheral | 2 | 2021 | 38 | 0.740 |
Why?
|
| Coronary Stenosis | 2 | 2013 | 246 | 0.730 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2011 | 139 | 0.710 |
Why?
|
| Vascular Calcification | 1 | 2020 | 131 | 0.670 |
Why?
|
| Pulse | 1 | 2017 | 23 | 0.590 |
Why?
|
| Wrist | 1 | 2017 | 24 | 0.580 |
Why?
|
| Vascular Malformations | 1 | 2017 | 19 | 0.570 |
Why?
|
| Transfusion Reaction | 1 | 2016 | 33 | 0.550 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2014 | 373 | 0.520 |
Why?
|
| Blood Transfusion | 1 | 2016 | 205 | 0.500 |
Why?
|
| Vitamin K | 1 | 2014 | 14 | 0.490 |
Why?
|
| Treatment Outcome | 11 | 2021 | 7029 | 0.470 |
Why?
|
| Femoral Artery | 2 | 2021 | 139 | 0.470 |
Why?
|
| Ticlopidine | 1 | 2014 | 118 | 0.460 |
Why?
|
| Coronary Restenosis | 1 | 2013 | 42 | 0.450 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 232 | 0.450 |
Why?
|
| Odds Ratio | 5 | 2016 | 880 | 0.440 |
Why?
|
| Heart Failure, Diastolic | 1 | 2012 | 14 | 0.420 |
Why?
|
| Cardiac Catheterization | 2 | 2021 | 419 | 0.410 |
Why?
|
| Anticoagulants | 1 | 2014 | 356 | 0.400 |
Why?
|
| Myocardial Revascularization | 1 | 2011 | 56 | 0.390 |
Why?
|
| Insulin Resistance | 1 | 2013 | 241 | 0.390 |
Why?
|
| Coronary Angiography | 6 | 2020 | 866 | 0.370 |
Why?
|
| Chi-Square Distribution | 4 | 2016 | 546 | 0.370 |
Why?
|
| Developing Countries | 2 | 2009 | 106 | 0.370 |
Why?
|
| Pulmonary Artery | 1 | 2013 | 323 | 0.360 |
Why?
|
| Intensive Care Units | 1 | 2012 | 344 | 0.350 |
Why?
|
| Hypertension, Pulmonary | 1 | 2013 | 232 | 0.350 |
Why?
|
| Humans | 27 | 2021 | 68618 | 0.340 |
Why?
|
| Registries | 5 | 2016 | 733 | 0.330 |
Why?
|
| Patient Compliance | 1 | 2011 | 402 | 0.320 |
Why?
|
| Risk Assessment | 5 | 2016 | 2007 | 0.320 |
Why?
|
| Aged | 13 | 2016 | 14862 | 0.320 |
Why?
|
| Risk Factors | 10 | 2021 | 5731 | 0.320 |
Why?
|
| Female | 18 | 2017 | 38074 | 0.300 |
Why?
|
| Middle Aged | 14 | 2017 | 21147 | 0.280 |
Why?
|
| Guideline Adherence | 1 | 2009 | 287 | 0.270 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2013 | 756 | 0.270 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 1046 | 0.270 |
Why?
|
| Male | 16 | 2016 | 37321 | 0.250 |
Why?
|
| Delivery of Health Care | 1 | 2009 | 445 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 772 | 0.230 |
Why?
|
| Logistic Models | 3 | 2016 | 1420 | 0.220 |
Why?
|
| United States | 5 | 2021 | 7367 | 0.190 |
Why?
|
| Atherectomy | 1 | 2020 | 7 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 1745 | 0.180 |
Why?
|
| Retrospective Studies | 7 | 2016 | 7277 | 0.180 |
Why?
|
| Biomarkers | 2 | 2016 | 1593 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 1465 | 0.170 |
Why?
|
| Punctures | 1 | 2017 | 35 | 0.150 |
Why?
|
| Angiography | 1 | 2017 | 194 | 0.140 |
Why?
|
| Propensity Score | 1 | 2016 | 117 | 0.140 |
Why?
|
| Shock, Cardiogenic | 1 | 2016 | 23 | 0.130 |
Why?
|
| Hemoglobins | 1 | 2016 | 120 | 0.130 |
Why?
|
| Creatinine | 1 | 2016 | 243 | 0.130 |
Why?
|
| Anemia | 1 | 2016 | 104 | 0.130 |
Why?
|
| International Normalized Ratio | 1 | 2014 | 23 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2014 | 82 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2016 | 682 | 0.120 |
Why?
|
| Time Factors | 3 | 2016 | 4655 | 0.110 |
Why?
|
| Treatment Failure | 1 | 2013 | 216 | 0.110 |
Why?
|
| Dilatation, Pathologic | 1 | 2013 | 58 | 0.110 |
Why?
|
| Cause of Death | 1 | 2013 | 241 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 180 | 0.100 |
Why?
|
| Multidetector Computed Tomography | 1 | 2013 | 60 | 0.100 |
Why?
|
| Prognosis | 3 | 2013 | 2093 | 0.100 |
Why?
|
| Incidence | 2 | 2014 | 1603 | 0.100 |
Why?
|
| Ventricular Function | 1 | 2012 | 93 | 0.100 |
Why?
|
| Diastole | 1 | 2012 | 161 | 0.100 |
Why?
|
| Lung Transplantation | 1 | 2013 | 88 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 244 | 0.100 |
Why?
|
| Lipids | 1 | 2013 | 298 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 504 | 0.100 |
Why?
|
| Pulsatile Flow | 1 | 2010 | 20 | 0.090 |
Why?
|
| Insulin | 1 | 2013 | 619 | 0.090 |
Why?
|
| Linear Models | 1 | 2011 | 521 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2013 | 631 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2010 | 169 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 931 | 0.080 |
Why?
|
| Myocardial Stunning | 1 | 2009 | 2 | 0.080 |
Why?
|
| Prevalence | 1 | 2013 | 1619 | 0.080 |
Why?
|
| Hospitalization | 1 | 2014 | 978 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2010 | 146 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2013 | 1330 | 0.080 |
Why?
|
| Stents | 1 | 2013 | 657 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 694 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1851 | 0.080 |
Why?
|
| Heart-Assist Devices | 1 | 2010 | 221 | 0.070 |
Why?
|
| Echocardiography | 1 | 2010 | 515 | 0.070 |
Why?
|
| Disease Progression | 1 | 2011 | 1038 | 0.070 |
Why?
|
| Proton Pump Inhibitors | 1 | 2008 | 91 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2279 | 0.070 |
Why?
|
| Animals | 2 | 2015 | 20881 | 0.070 |
Why?
|
| Heptanoic Acids | 1 | 2006 | 28 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2010 | 738 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 185 | 0.070 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2006 | 80 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 4848 | 0.070 |
Why?
|
| Pyrroles | 1 | 2006 | 83 | 0.070 |
Why?
|
| Coronary Artery Bypass | 2 | 2021 | 218 | 0.060 |
Why?
|
| Lebanon | 3 | 2010 | 67 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 377 | 0.060 |
Why?
|
| Heart Failure | 1 | 2010 | 1180 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2016 | 384 | 0.050 |
Why?
|
| Adult | 3 | 2014 | 21403 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 3259 | 0.040 |
Why?
|
| Comorbidity | 2 | 2016 | 1426 | 0.040 |
Why?
|
| Norway | 1 | 2014 | 18 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2014 | 291 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2010 | 172 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 242 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 2010 | 110 | 0.020 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2010 | 155 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 189 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 202 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 166 | 0.020 |
Why?
|
| Internationality | 1 | 2009 | 74 | 0.020 |
Why?
|
| Rabeprazole | 1 | 2008 | 1 | 0.020 |
Why?
|
| Proton-Translocating ATPases | 1 | 2008 | 9 | 0.020 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2008 | 23 | 0.020 |
Why?
|
| Aspirin | 1 | 2010 | 295 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2010 | 277 | 0.020 |
Why?
|
| Omeprazole | 1 | 2008 | 53 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1054 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 498 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 90 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 320 | 0.020 |
Why?
|
| Cholesterol | 1 | 2006 | 331 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 1753 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2006 | 383 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2006 | 601 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 2077 | 0.010 |
Why?
|
| Obesity | 1 | 2005 | 1076 | 0.010 |
Why?
|
| Hypertension | 1 | 2005 | 1535 | 0.010 |
Why?
|